PMID Antimicrobial dosing considerations in obese adult patients. Clin Infect Dis. PMID: Comparative evaluation of atracurium dosed on ideal body weight vs. Br J Clin Pharmacol. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Ann Pharmacother. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting.
Intensive Care Med. Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Am J Health Syst Pharm. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis. Optimal weight base for a weight-based heparin dosing protocol.
Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature. UK Department of Health. Clinical Guidelines for Immunoglobulin Use.
Available at GOV. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Casati A, Putzu M.
Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther. J Antimicrob Chemother.
Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Phenytoin disposition in obesity. Determination of loading dose. Arch Neurol. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.
Bone Marrow Transplant. Remifentanil pharmacokinetics in obese versus lean patients. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg. The dose of succinylcholine in morbid obesity. Pai MP. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. Quantification of lean bodyweight. Clin Pharmacokinet. Follow Us!
Get Email Updates. Open Menu. Drug Dosing in Obesity Reference Table. Updated July 15, Accessed November 12, All rights reserved. Female Male. Dosing Weight for obese or overweight patients. Select Dosing, then click "Calculate".
Height must be between cm inches. Weight must be between kg pounds. Dosing Weight is an adjusted body weight of obese or overweight patients and should only be used to calculate the dose of drugs for which there are recommendations specifying that the actual body weight should be adjusted for use in the dose calculations. References: 1. The origin of the "ideal" body weight equations.
Ann Pharmacother. Sep;34 9
0コメント